We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current IPIX market cap is 1.35M. The company's latest EPS is USD -0.0061 and P/E is 0.00.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 423k | 0 | 18k | 0 |
| Operating Income | -6.45M | -4.64M | -9.02M | -6.92M | -3.11M |
| Net Income | -8.68M | -6.65M | -13.87M | -7.04M | -3.17M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 4.05M | 9.25M | 14.3M | 10.38M | 7.52M |
| Total Liabilities | 8.18M | 7.79M | 6.79M | 5.65M | 5.48M |
| Total Equity | -4.13M | 1.46M | 7.51M | 4.73M | 2.04M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -6.33M | -4.16M | -9.5M | -6.28M | -2.11M |
| Investing | -46k | -91k | -72k | -4.08M | -60k |
| Financing | 4.53M | 9.69M | 13.74M | 3.97M | -123k |
| Market Cap | 1.35M |
| Price to Earnings Ratio | 0.00 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 518.35M |
| Average Volume (1 week) | 96.72k |
| Average Volume (1 Month) | 472.03k |
| 52 Week Change | -85.75% |
| 52 Week High | 0.023 |
| 52 Week Low | 0.0001 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Innovation Pharmaceuticals Inc (CE) |
| Address |
701 s. carson street carson city, nevada 89701 |
| Website | https://www.ipharminc.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
